Cargando…

Improvement in Serum Magnesium Levels With Sodium-Glucose Cotransporter 2 Inhibitors

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are associated with a modest but significant increase in serum magnesium levels. This report describes improvement in serum magnesium and associated symptoms after initiating SGLT2i therapy in a patient with refractory hypomagnesemia. A 58-year-old...

Descripción completa

Detalles Bibliográficos
Autores principales: Saha, Arunava, Omer, Abdulkadir, Trivedi, Nitin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578385/
https://www.ncbi.nlm.nih.gov/pubmed/37908255
http://dx.doi.org/10.1210/jcemcr/luac018
_version_ 1785121508687872000
author Saha, Arunava
Omer, Abdulkadir
Trivedi, Nitin
author_facet Saha, Arunava
Omer, Abdulkadir
Trivedi, Nitin
author_sort Saha, Arunava
collection PubMed
description Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are associated with a modest but significant increase in serum magnesium levels. This report describes improvement in serum magnesium and associated symptoms after initiating SGLT2i therapy in a patient with refractory hypomagnesemia. A 58-year-old woman presented with persistent hypomagnesemia refractory to oral magnesium supplements. She had history of type 2 diabetes mellitus, hypothyroidism, fibromyalgia, and degenerative disk disease. The cause of hypomagnesemia was attributed to excessive renal losses. Laboratory investigations revealed serum magnesium of 1.2 mg/dL with fractional excretion of magnesium of 8.9%. She was started on empagliflozin 10 mg daily. Within 4 weeks of therapy, her serum magnesium level corrected with symptomatic improvement, which was sustained a few weeks later. Subsequently, her oral magnesium supplements dose was reduced. SGLT2i has been shown to improve magnesium levels in patients with urinary magnesium wasting. Several mechanisms have been postulated, but the exact physiology remains unknown. SGLT2i have been efficacious for glycemic control, renal protection, decreasing the risk of atherosclerotic cardiovascular disease events, and cardiac mortality in patients with diabetes. In addition, renal and cardiac benefits are also demonstrated in patients without diabetes. This observation demonstrates that SGLT2i can improve the management of patients with otherwise intractable hypomagnesemia.
format Online
Article
Text
id pubmed-10578385
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105783852023-10-31 Improvement in Serum Magnesium Levels With Sodium-Glucose Cotransporter 2 Inhibitors Saha, Arunava Omer, Abdulkadir Trivedi, Nitin JCEM Case Rep Case Report Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are associated with a modest but significant increase in serum magnesium levels. This report describes improvement in serum magnesium and associated symptoms after initiating SGLT2i therapy in a patient with refractory hypomagnesemia. A 58-year-old woman presented with persistent hypomagnesemia refractory to oral magnesium supplements. She had history of type 2 diabetes mellitus, hypothyroidism, fibromyalgia, and degenerative disk disease. The cause of hypomagnesemia was attributed to excessive renal losses. Laboratory investigations revealed serum magnesium of 1.2 mg/dL with fractional excretion of magnesium of 8.9%. She was started on empagliflozin 10 mg daily. Within 4 weeks of therapy, her serum magnesium level corrected with symptomatic improvement, which was sustained a few weeks later. Subsequently, her oral magnesium supplements dose was reduced. SGLT2i has been shown to improve magnesium levels in patients with urinary magnesium wasting. Several mechanisms have been postulated, but the exact physiology remains unknown. SGLT2i have been efficacious for glycemic control, renal protection, decreasing the risk of atherosclerotic cardiovascular disease events, and cardiac mortality in patients with diabetes. In addition, renal and cardiac benefits are also demonstrated in patients without diabetes. This observation demonstrates that SGLT2i can improve the management of patients with otherwise intractable hypomagnesemia. Oxford University Press 2022-11-30 /pmc/articles/PMC10578385/ /pubmed/37908255 http://dx.doi.org/10.1210/jcemcr/luac018 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Saha, Arunava
Omer, Abdulkadir
Trivedi, Nitin
Improvement in Serum Magnesium Levels With Sodium-Glucose Cotransporter 2 Inhibitors
title Improvement in Serum Magnesium Levels With Sodium-Glucose Cotransporter 2 Inhibitors
title_full Improvement in Serum Magnesium Levels With Sodium-Glucose Cotransporter 2 Inhibitors
title_fullStr Improvement in Serum Magnesium Levels With Sodium-Glucose Cotransporter 2 Inhibitors
title_full_unstemmed Improvement in Serum Magnesium Levels With Sodium-Glucose Cotransporter 2 Inhibitors
title_short Improvement in Serum Magnesium Levels With Sodium-Glucose Cotransporter 2 Inhibitors
title_sort improvement in serum magnesium levels with sodium-glucose cotransporter 2 inhibitors
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578385/
https://www.ncbi.nlm.nih.gov/pubmed/37908255
http://dx.doi.org/10.1210/jcemcr/luac018
work_keys_str_mv AT sahaarunava improvementinserummagnesiumlevelswithsodiumglucosecotransporter2inhibitors
AT omerabdulkadir improvementinserummagnesiumlevelswithsodiumglucosecotransporter2inhibitors
AT trivedinitin improvementinserummagnesiumlevelswithsodiumglucosecotransporter2inhibitors